Eureka AIR delivers breakthrough ideas for toughest innovation challenges, trusted by R&D personnel around the world.

Drug combination composition for treating tumor diseases and application

A combined drug and composition technology, applied in the field of biomedicine, can solve the problem of the lack of approval and marketing of the combined drug of anti-PD-1 monoclonal antibody and anti-EGFR monoclonal antibody, so as to prolong progression-free survival and overall survival, and improve treatment Effects on duration of response, improved health status, and quality of life

Pending Publication Date: 2022-03-11
BEIJING DONGFANG BIOTECH
View PDF1 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0003] At present, there are many drugs that can be used in combination with anti-PD-1 monoclonal antibodies, but there is still no approval for the combination of anti-PD-1 monoclonal antibodies and anti-EGFR monoclonal antibodies

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Drug combination composition for treating tumor diseases and application
  • Drug combination composition for treating tumor diseases and application
  • Drug combination composition for treating tumor diseases and application

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0028] Example 1 of the present invention provides a combination drug composition for treating tumor diseases, including an anti-PD-1 monoclonal antibody targeting PD-1 and an anti-EGFR monoclonal antibody targeting EGFR.

[0029] Anti-PD-1 monoclonal antibodies include DFPD1-9, DFPD1-10, DFPD1-11, DFPD1-12, DFPD1-13, Nivolumab, Pembrolizumab, toripalimab, sintilimab, tislelizumab Antibodies, camrelizumab, pembrolizumab, or cepalimumab.

[0030] Among them, Nivolumab, Pembrolizumab, Toripalimab, Sintilimab, Tislelizumab, Camrelizumab, Pembrolizumab or Sepalimumab are all listed products .

[0031] Among them, DFPD1-9, DFPD1-10, DFPD1-11, DFPD1-12, and DFPD1-13 are the anti-PD-1 monoclonal antibodies provided by the application number CN201510312910.8, and DFPD1-9 includes as shown in SEQ ID No: 2 The light chain variable region shown and the heavy chain variable region shown in SEQ ID No: 1; DFPD1-10 includes the light chain variable region shown in SEQ ID No: 3 and the heav...

Embodiment 2

[0047] On the basis of Example 1, Example 2 of the present invention provides a combination drug composition for treating tumor diseases, including an anti-PD-1 monoclonal antibody targeting PD-1 and an anti-EGFR targeting EGFR Monoclonal antibodies.

[0048] The anti-PD-1 monoclonal antibody is DFPD1-10, and DFPD1-10 includes a light chain variable region as shown in SEQ ID No:3 and a heavy chain variable region as shown in SEQ ID No:1.

[0049] The anti-EGFR monoclonal antibody is Nimotuzumab.

[0050] The administration of DFPD1-10 and Nimotuzumab was sequential.

[0051] Both DFPD1-10 and nimotuzumab were administered intravenously.

[0052] The dosage of DFPD1-10 is 100mg;

[0053] The dosage of Nimotuzumab is 100mg;

[0054] The dosing cycle of DFPD1-10 was every two weeks, and the dosing cycle of nimotuzumab was once a week.

Embodiment 3

[0056] Example 3 of the present invention further limits the dosage of DFPD1-10 to 200mg on the basis of Example 2;

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
Weightaaaaaaaaaa
Login to View More

Abstract

The invention relates to the field of biological medicines, and particularly provides a drug combination composition for treating tumor diseases, which comprises an anti-PD-1 monoclonal antibody taking PD-1 as a target spot and an anti-EGFR monoclonal antibody taking EGFR as a target spot. According to the invention, the anti-PD-1 monoclonal antibody and the anti-EGFR monoclonal antibody are combined for use, so that the medication safety is higher, the treatment response duration is effectively prolonged, the progression-free lifetime and the total lifetime of cancer patients are prolonged, the health condition and the life quality of the patients are improved, and the clinical application prospect is wide. The combined medicine composition can be used for treating non-small cell lung cancer, metastatic non-small cell lung cancer, glioma, colorectal cancer, liver cancer, hepatocellular carcinoma, metastatic hepatocellular carcinoma, HER2 negative metastatic breast cancer, metastatic gastric adenocarcinoma, metastatic colorectal cancer, metastatic melanoma, metastatic renal cell carcinoma and advanced esophageal squamous carcinoma. Advanced squamous non-small cell lung cancer or advanced head and neck squamous cell cancer.

Description

technical field [0001] The invention relates to the technical field of biomedicine, in particular to a combined drug composition and application for treating tumor diseases. Background technique [0002] Immunotherapy is a hot field of tumor treatment, and PD-1 target is currently a hot target for immunotherapy. PD-1 is a key immune checkpoint receptor expressed on the surface of activated T cells. After encountering PD-L1 and PD-L2 ligand molecules on the surface of tumor cells, it inhibits the activation of T cells and invading tumor cells It will escape the surveillance of the immune system, while the use of anti-PD-1 monoclonal antibody inhibitors will relieve the inhibition of tumor cells on T cell activation, and the T cells of the patient's own immune system will be activated in large numbers, thereby killing tumor cells. At present, a number of monoclonal antibodies targeting PD-1 are already on the market at home and abroad, and many anti-PD-1 monoclonal antibodies...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K39/395C07K16/28A61P35/04A61P35/00
CPCC07K16/2818C07K16/2863A61K39/3955A61P35/00A61P35/04C07K2317/56C07K2317/73A61K2039/507A61K2300/00
Inventor 白义
Owner BEIJING DONGFANG BIOTECH
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com